Sign In
Buy ELAN
Elanco Animal Health Earnings Calls
| Release date | Nov 05, 2025 |
| EPS estimate | $0.130 |
| EPS actual | $0.190 |
| EPS Surprise | 46.15% |
| Revenue estimate | 1.095B |
| Revenue actual | 1.137B |
| Revenue Surprise | 3.88% |
| Release date | Aug 07, 2025 |
| EPS estimate | $0.200 |
| EPS actual | $0.260 |
| EPS Surprise | 30.00% |
| Revenue estimate | 1.089B |
| Revenue actual | 1.241B |
| Revenue Surprise | 13.91% |
| Release date | May 07, 2025 |
| EPS estimate | $0.310 |
| EPS actual | $0.370 |
| EPS Surprise | 19.35% |
| Revenue estimate | 1.178B |
| Revenue actual | 1.193B |
| Revenue Surprise | 1.28% |
| Release date | Feb 25, 2025 |
| EPS estimate | $0.160 |
| EPS actual | $0.140 |
| EPS Surprise | -12.50% |
| Revenue estimate | 1.21B |
| Revenue actual | 1.02B |
| Revenue Surprise | -15.70% |
Last 4 Quarters for Elanco Animal Health
Below you can see how ELAN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 25, 2025 |
| Price on release | $10.70 |
| EPS estimate | $0.160 |
| EPS actual | $0.140 |
| EPS surprise | -12.50% |
| Date | Price |
|---|---|
| Feb 19, 2025 | $11.24 |
| Feb 20, 2025 | $11.13 |
| Feb 21, 2025 | $11.02 |
| Feb 24, 2025 | $11.11 |
| Feb 25, 2025 | $10.70 |
| Feb 26, 2025 | $11.13 |
| Feb 27, 2025 | $10.92 |
| Feb 28, 2025 | $11.17 |
| Mar 03, 2025 | $11.31 |
| 4 days before | -4.80% |
| 4 days after | 5.70% |
| On release day | 4.02% |
| Change in period | 0.623% |
| Release date | May 07, 2025 |
| Price on release | $12.01 |
| EPS estimate | $0.310 |
| EPS actual | $0.370 |
| EPS surprise | 19.35% |
| Date | Price |
|---|---|
| May 01, 2025 | $9.47 |
| May 02, 2025 | $9.75 |
| May 05, 2025 | $9.65 |
| May 06, 2025 | $9.51 |
| May 07, 2025 | $12.01 |
| May 08, 2025 | $12.28 |
| May 09, 2025 | $11.96 |
| May 12, 2025 | $12.82 |
| May 13, 2025 | $13.02 |
| 4 days before | 26.82% |
| 4 days after | 8.41% |
| On release day | 2.25% |
| Change in period | 37.49% |
| Release date | Aug 07, 2025 |
| Price on release | $16.48 |
| EPS estimate | $0.200 |
| EPS actual | $0.260 |
| EPS surprise | 30.00% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $13.79 |
| Aug 04, 2025 | $14.07 |
| Aug 05, 2025 | $14.20 |
| Aug 06, 2025 | $13.95 |
| Aug 07, 2025 | $16.48 |
| Aug 08, 2025 | $16.67 |
| Aug 11, 2025 | $17.10 |
| Aug 12, 2025 | $17.43 |
| Aug 13, 2025 | $17.81 |
| 4 days before | 19.51% |
| 4 days after | 8.07% |
| On release day | 1.15% |
| Change in period | 29.15% |
| Release date | Nov 05, 2025 |
| Price on release | $21.60 |
| EPS estimate | $0.130 |
| EPS actual | $0.190 |
| EPS surprise | 46.15% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $22.57 |
| Oct 31, 2025 | $22.15 |
| Nov 03, 2025 | $22.85 |
| Nov 04, 2025 | $22.50 |
| Nov 05, 2025 | $21.60 |
| Nov 06, 2025 | $21.52 |
| Nov 07, 2025 | $21.49 |
| Nov 10, 2025 | $22.26 |
| Nov 11, 2025 | $22.86 |
| 4 days before | -4.30% |
| 4 days after | 5.83% |
| On release day | -0.370% |
| Change in period | 1.28% |
Elanco Animal Health Earnings Call Transcript Summary of Q3 2025
Elanco reported strong Q3 2025 results, driven by broad-based organic constant currency revenue growth of 9% (reported revenue $1.137B). Key growth drivers were U.S. farm animal (+20%) and U.S. pet health (+9%), with innovation revenue reaching $655M year-to-date and management raising full-year innovation guidance to $840M–$880M. The company raised full-year guidance (organic revenue growth 6%–6.5%; adjusted EBITDA $880M–$900M; adjusted EPS $0.91–$0.94) after outperforming prior targets. Cash generation and deleveraging progressed faster than planned: net debt was about $3.3B with a net leverage ratio of 3.7x at quarter-end, and a $2.1B Term Loan B was refinanced into facilities extending maturities to 2029/2032. Management highlighted strong launches—notably Credelio Quattro (fastest blockbuster in Elanco history, $100M in ~8 months) and Zenrelia (accelerating adoption and positive label developments in the U.S.)—and reiterated the IPP strategy (Innovation, Portfolio, Productivity) with Elanco Ascend targeted to drive margin expansion beginning in 2026. Tariffs remain a manageable headwind (expected $10M–$14M net impact in 2025). Management expects continued top-line and EBITDA growth in 2026, with further deleveraging toward sub-3x net leverage over time and additional detail to be provided at the December 9 Investor Day.
